Browsing category:

OTC and Compounding Product


As the most commonly prescribed treatment for glaucoma, Latanoprost has taken the pharmaceutical headlines by storm with the latest study data revelations. At the end of December 2014 The Lancet published remarkable study results indicating that the use of Latanoprost reduced the risk of glaucoma by over 50 percent when taken for two years’ time.[…]

Read More

British-Swedish drugmaker AstraZeneca has been approved by the FDA for its once-a-day Xigduo XR extended-release tablet to treat adults with type 2 diabetes mellitus in the United States. AstraZeneca’s once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control. Xigduo XR is already approved in Australia, and Xigduo is[…]

Read More

On September 10, 2014, The U.S. Food and Drug Administration (US FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) for anti-obesity treatments in combination with a reduced-calorie diet and exercise. Contrave is distributed by Takeda Pharmaceuticals America Inc. of Deerfield, Illinois for Orexigen Therapeutics, Inc. of La Jolla, California. The FDA approved the[…]

Read More

The USFDA has received the Aripiprazole Lauroxil NDA, submitted by Ireland-based Alkermes for treating patients with schizophrenia. Alkermes shares gained almost 2.3% on the news. Aripiprazole lauroxil is a partial dopamine agonist of the second generation class of antipsychotics, with one-month and two-month formulations, developed for the treatment of the mental disorder schizophrenia, which is[…]

Read More

The FDA concluded its safety review of the popular anti-hypertensive drug Olmesartan, also known as the brand name Benicar, in June 2014. There was no viable evidence found to cause the FDA to deem Olmesartan unsafe, and earlier concerns from study investigators claiming there was an increased risk for heart attack in patients taking Olmesartan[…]

Read More

The end of June 2014 brought exciting news for Insmed’s liposomal Amikacin, known as the brand name Arikace, with a Breakthrough Status award from the FDA. Amikacin was specifically designated Breakthrough Status for treatment refractory nontuberculous mycobacterial lung disease in adult patients. As an inhaled antibiotic Amikacin is effectual for treating chronic nontuberculous mycobacterial lung[…]

Read More

As the leading cause of blindness in the United States Diabetic Macular Edema {DME} is a serious concern for the growing aging population, affecting roughly one million Americans. The recent announcement from pSivida Corp. regarding the marketing authorization in the EU of their DME treatment Fluocinolone is hopeful for U.S. supporters of this formidable drug.[…]

Read More

Approximately four million Americans undergo cataract surgery every year, so the recent FDA approval of Ketorolac and Phenylephrine on June 2, 2014 is timely and beneficial for many patients in the United States. Known as the brand name Omidria, the combination of Ketorolac and Phenylephrine to create an efficacious pupil-dilating agent has been deemed successful[…]

Read More

As a debilitating disease which destroys the muscles Duchenne Muscular Dystrophy, also known as DMD is a genetic disorder. DMD affects mainly males, and it is characterized by extreme muscle fatigue and excessive muscle degeneration. The cause of Duchenne Muscular Dystrophy is a lack of dystrophin in the body, which is the necessary protein that[…]

Read More

The recent FDA approval for AstraZeneca’s Nexium 24 hour, or Esomeprazole, was exciting news for the pharmaceutical world. With over sixty million Americans suffering from heartburn at least once a month the advent of a 24 hour treatment that is easy to access is relieving. As an OTC or over the counter treatment for gastroesophageal[…]

Read More